Cystadenocarcinoma, Serous  >>  paclitaxel  >>  Phase 1
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
paclitaxel / Generic mfg.
NCT00003385: Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed
1
48
US, Europe
carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
01/07
 
NCT00005026: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Completed
1
US, Canada
carboplatin, paclitaxel, topotecan hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
01/07
 
NCT00002913: Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Completed
1
30
US
paclitaxel, Anzatax, Asotax, TAX, Taxol, cisplatin, CACP, CDDP, CPDD, DDP, topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, filgrastim, G-CSF, Neupogen
National Cancer Institute (NCI)
Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
07/07
 
NCT00005840: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Completed
1
35
US
Paclitaxel, Anzatax, TAX, Cisplatin, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
07/09
 
NCT00814086: Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Completed
1
23
US
Paclitaxel, Anzatax, TAX, Cisplatin
Gynecologic Oncology Group, National Cancer Institute (NCI)
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication, Malignant Ovarian Mixed Epithelial Tumor, Neurotoxicity Syndrome, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated Ovarian Carcinoma
07/11
 
NCT01294293: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed
1
20
US
TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337, VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies, Pegylated Liposomal Doxorubicin Hydrochloride, doxorubicin HCl liposome, TLC D-99, Paclitaxel, Anzatax, TAX
Gynecologic Oncology Group, National Cancer Institute (NCI)
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
07/14
 
NCT02050009: Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Withdrawn
1
0
US
metformin hydrochloride, Glucophage, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel, Anzatax, Asotax, TAX, Taxol, laboratory biomarker analysis
Fox Chase Cancer Center, National Cancer Institute (NCI)
Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer
10/14
10/14
NCT01440998: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Completed
1
18
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Dasatinib, BMS-354825, Sprycel, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
12/15
12/15
NCT00575952: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Completed
1
27
US
Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Paclitaxel, Pegfilgrastim
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
07/16
07/16

Download Options